Crospovidone
CAS 9003-39-8
Crospovidone (CAS 9003-39-8) is a pharmaceutical compound with 0 bioactivity targets and 89 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| CROSPOVIDONE | 1310706 | SU | MTHSPL |
| crospovidone | 1310706 | SU | MTHSPL |
| Crospovidone | 1310706 | SU | MTHSPL |
| CROSPOVIDONE | 2109746 | SU | MTHSPL |
| Crospovidone | 2109746 | SU | MTHSPL |
| crospovidone | 2109746 | SU | MTHSPL |
| crospovidone | 1310706 | IN | RXNORM |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Crospovidone used for in pharmaceutical contexts?
Crospovidone (CAS 9003-39-8) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Crospovidone?
Crospovidone has 89 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Caesarean section, Maternal exposure during pregnancy, Anaphylactic reaction, Condition aggravated, Expired product administered. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Crospovidone also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for PVP with EU status "permitted".
What clinical phase is Crospovidone in?
No phase 1-4 clinical development badge is rendered for Crospovidone because the matched compound identifier rows do not contain a max-phase value.